MASLD: semaglutide and resmetirom explained

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, and until recently it had no approved drug treatment. That changed when two agents cleared phase 3 trials and received conditional FDA approval for the subset of MASLD patients with active steatohepatitis and clinically significant fibrosis (fibrosis stage F2 or F3): resmetirom, a liver-directed thyroid hormone receptor-beta agonist, and semaglutide 2.4 mg weekly, the GLP-1 receptor agonist already established in obesity and type-2 diabetes.^[5]

The approvals matter because the prior standard of care was lifestyle modification alone: caloric restriction, exercise, and weight loss. For patients with F2 or F3 fibrosis who cannot achieve or sustain sufficient weight loss through lifestyle changes, there was no pharmacological fallback. Now there are two.

What MASLD and MASH actually mean

The nomenclature shifted in 2023. Non-alcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic steatohepatitis (NASH) became metabolic dysfunction-associated steatohepatitis (MASH). The disease is a spectrum: fat in liver cells (steatosis) can progress to inflammation and hepatocellular injury (steatohepatitis), which can then drive fibrosis, cirrhosis, and ultimately hepatocellular carcinoma.

Not everyone with steatosis progresses. The subset that does tends to carry obesity, type-2 diabetes, hypertension, or dyslipidaemia, which is why MASLD has emerged as a condition that sits at the intersection of hepatology and metabolic medicine. The two drugs now approved reflect that overlap.

Semaglutide in MASH: the ESSENCE trial

The phase 3 ESSENCE trial (Sanyal et al., NEJM 2025) enrolled 800 adults with biopsy-confirmed MASH and fibrosis stage 2 or 3 in its interim analysis. Participants received once-weekly subcutaneous semaglutide 2.4 mg or placebo for up to 240 weeks. The interim results reported 62.9% of participants on semaglutide achieving resolution of steatohepatitis without fibrosis worsening, compared with 34.3% on placebo, a difference of 28.7 percentage points (95% CI 21.1 to 36.2; P less than 0.001).^[2]

Fibrosis improvement by at least one stage without steatohepatitis worsening occurred in 36.8% on semaglutide versus 22.4% on placebo, a difference of 14.4 percentage points (95% CI 7.5 to 21.3; P less than 0.001). The combined endpoint of both MASH resolution and fibrosis improvement was reached by 32.7% on semaglutide versus 16.1% on placebo.^[2] Mean body-weight reduction was 10.5% on semaglutide versus 2.0% on placebo.

A secondary analysis of the ESSENCE data examined whether those liver benefits were driven by weight loss alone or whether semaglutide had direct hepatic effects beyond weight reduction. The finding was that histological and non-invasive test improvements occurred across all body-weight-reduction thresholds,^[3] suggesting both pathways are at work. That distinction matters clinically because patients with limited weight loss on semaglutide may still derive liver benefit.

Resmetirom in MASH: the MAESTRO-NASH trial

Resmetirom targets a different mechanism. Thyroid hormone receptor-beta (THR-beta) is the dominant receptor subtype in liver cells and plays a role in lipid metabolism and mitochondrial function. By selectively activating THR-beta in hepatic tissue, resmetirom aims to reduce hepatic lipid accumulation and inflammation without the cardiac and bone side effects associated with systemic thyroid hormone activation. The MAESTRO-NASH trial (Harrison et al., NEJM 2024, PMID 38324483) was the phase 3 programme that supported FDA approval.^[4]

Unlike semaglutide, resmetirom does not produce meaningful body-weight reduction. Its liver effects appear to be largely weight-independent, working through direct metabolic reprogramming of hepatocytes. Both drugs are now conditionally approved for non-cirrhotic MASH with F2 or F3 fibrosis, which means the clinical decision about which to use involves factors beyond efficacy alone: weight management goals, cardiovascular risk, tolerability, and whether type-2 diabetes is present.

Where GLP-1 receptor agonists fit more broadly

A 2026 meta-analysis of the semaglutide MASLD evidence base (Peng et al., British Journal of Clinical Pharmacology) pooled the available trial data and found a statistically significant improvement in MASH resolution without fibrosis worsening (odds ratio 3.48; 95% CI 2.68 to 4.53; P less than 0.00001) alongside a significant increase in relative liver fat reduction of 30% or more (odds ratio 7.16; 95% CI 3.08 to 16.64).^[1] Fibrosis improvement alone was not statistically significant in the pooled analysis (odds ratio 1.17; P 0.72), consistent with the ESSENCE interim results where fibrosis improvement, though present, was smaller in absolute terms than MASH resolution.

A separate 2026 systematic review of the whole GLP-1 receptor agonist class in non-alcoholic fatty liver disease (Mahoon et al., International Journal of Molecular Sciences) confirmed that hepatic fat reduction was the most consistent outcome across agents including semaglutide, liraglutide, dulaglutide, and beinaglutide, with histological MASH resolution strongest in patients without cirrhosis.^[6] Benefits in F4 (cirrhotic) MASH remain limited and are not part of current approved indications.

What is not settled

Several questions remain open. Cirrhotic MASH (fibrosis stage F4) has no approved pharmacological therapy as of 2026: effective treatments at that stage could prevent decompensation and hepatocellular carcinoma, but neither resmetirom nor semaglutide is indicated there. Long-term durability data past the interim readout window are pending for ESSENCE, which continues to a 240-week endpoint. The cardiovascular benefits of semaglutide in MASLD patients specifically, as opposed to the broader GLP-1 class cardiovascular outcomes trial evidence, are not yet separately characterised. And combination therapy approaches, such as pairing a GLP-1 agonist with a fibrosis-targeted agent, are under investigation but have not yet produced pivotal trial data.

The 2026 state-of-the-art review by Chan et al. in the Journal of Obesity and Metabolic Syndrome (PMID 42421259)^[5] frames this as a genuinely new era: incretin-based therapies have become foundational for managing obesity-related metabolic disorders including MASLD, and the approved agents represent a real advance over lifestyle modification alone for patients with moderate to advanced fibrosis. The review also highlights emerging fibroblast growth factor-21 analogues and other pipeline agents, suggesting the treatment option set will continue to expand.

What this means for patients and clinicians

For patients with biopsy-confirmed MASH and F2 or F3 fibrosis who are also carrying obesity or type-2 diabetes, semaglutide offers the practical benefit of addressing both the liver disease and its metabolic drivers simultaneously. Resmetirom is an option for patients where weight reduction is not a primary goal or where GLP-1 tolerability is a concern. Both require clinical assessment and prescription; neither is available as an over-the-counter or research-use product.

Lifestyle modification remains foundational alongside either drug. The ESSENCE trial participants were enrolled with structured lifestyle support, and the pharmacological benefits observed should be understood in that context rather than as replacement for dietary and exercise changes.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.